Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DREIMS

Financiado

DRUG-ELUTING ELECTRICAL IMPLANT TO REPAIR THE SPINAL CORD

In Neurofibres (FET-PROACTIVE, 2017-2021), we accomplished a major therapeutic advance for spinal cord injury (SCI) by combining biomaterials, pharmaceuticals, and electrical stimulation into an innovative implant able to promote... ver más

30/11/2026

FUNDACIÓN HOSPITAL...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

FUNDACIÓN HOSPITAL NACIONAL PARAPLÉJICOS PARA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 802K€

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-06

HORIZON-EIC-2023-TRANSITIONCHALLENGES-01: EIC Transition Challenge: Full scal... Scope:The scope of the Challenge is the maturation of Micro-Nano-Bio technologies developed in previ...

I+D

Cerrada hace 1 año

0% 94% 100%

4 Participantes

FUNDACIÓN HOSPITAL NACIONAL...

1.04M€ | Lider

ALU-FR

706.04K€ | Participante

SPINAL CORD TECHNOLOGIES

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTI2018-095872-B-C21 NUEVO BIOMATERIAL BIO-ACTIVO PARA LA REGENERACION DE LESIONE... 242K€ Cerrado

RTI2018-095872-B-C22 NUEVO DISPOSITIVO BIOACTIVO PARA LA REGENERACION DE LESIONES... 218K€ Cerrado

PID2020-113480RB-I00 BIOIMPLANTES MAGNETICOS INTELIGENTES PARA REGENERACION NEURA... 218K€ Cerrado

PID2021-124839OA-I00 ESTRATEGIA COMBINATORIA: HIDROGELES MOVILES PARA LA MEJORA D... 127K€ Cerrado

MINECHPS-SCI Development of minimally invasive neuromodulatory electrocon... 216K€ Cerrado

MAT2015-66666-C3-2-R BIOHIBRIDOS PARA LA PROMOCION DEL CRECIMIENTO AXONAL Y LA RE... 121K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2023-10-06
Fecha Fin: 2026-11-30

Líder del proyecto

FUNDACIÓN HOSPITAL NACIONAL PARAPLÉJICOS PARA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 802K€

Presupuesto del proyecto 3M€

Descripción del proyecto In Neurofibres (FET-PROACTIVE, 2017-2021), we accomplished a major therapeutic advance for spinal cord injury (SCI) by combining biomaterials, pharmaceuticals, and electrical stimulation into an innovative implant able to promote the closure of the spinal cord gap, with axonal regrowth and glial cell migration across large lesions in rodent and porcine models of SCI. In brief, the implant comprised biofunctionalized, conducting polymer-coated carbon microfibres (MFs) that promoted aligned neural cell growth across the lesion, embedded within a drug-eluting hydrogel that filled the tissue defect and reduced fibrosis. These intraspinal elements were complemented with electrodes that provided biphasic electrical stimulation (ES) to the lesion and the perilesional tissue, thus inducing extensive neural regeneration. Building on the initial proof of concept achieved in Neurofibres (TRL 3), DREIMS will mature this novel healthcare technology through TRLs 4-5, becoming close to its approval for use in human therapeutics while creating a business plan to support further exploitation steps. The inventors of the implant filled a patent application (P202230626) on the mentioned results and recently created a spin-off company (Spinal Cord Technologies, SCT S.L.) to pursue the refinement and validation of a successful clinical and commercial medical product. DREIMS builds on those results to consolidate the first-in-class drug-eluting electrical implant to repair the spinal cord. The implant will refine and integrate three modules, namely the microfiber/drug-eluting gel bundles (MIBs) from FUHNPAIIN / SCT S.L. (Spain), spinal electrode arrays (SEAs) from ALU-FR/IMTEK (Germany), and a fully implantable electric pulse generator (IPG) from NEURINNOV (France), thus forming a procedure pack according to the European Medical Device Regulation (MDR) 2017/745. Addressing regulatory requirements and business development activities will increase the market readiness of the implant.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores